Articles by Jordan Axelrad, MD, MPH
Panelists discuss how understanding the causes of iron deficiency anemia, selecting appropriate treatments such as intravenous iron, and tailoring therapies to individual patient needs are critical for effective management, particularly in patients with gastrointestinal conditions.
Panelists discuss how understanding the causes of iron deficiency anemia, selecting appropriate treatments such as intravenous iron, and tailoring therapies to individual patient needs are critical for effective management, particularly in patients with gastrointestinal conditions.
Collaboration and Communication Across the Healthcare Team
ByMichael Auerbach, MD,Layla Van Doren, MD,Jordan Axelrad, MD, MPH,Steven Fein, MD, MPH,Ashley Benson, MD The expert panel concludes its discussion with insights on how collaboration and communication across various healthcare specialties improve the care of patients treated for iron deficiency anemia.
Treatment-Emergent Hypophosphatemia Following Administration of Intravenous Iron
ByMichael Auerbach, MD,Layla Van Doren, MD,Jordan Axelrad, MD, MPH,Steven Fein, MD, MPH,Ashley Benson, MD The panel discusses the mechanism of treatment-emergent hypophosphatemia that occurs following the administration of certain intravenous iron formulations.
Practical Tools for the Administration of Intravenous Iron
ByMichael Auerbach, MD,Layla Van Doren, MD,Jordan Axelrad, MD, MPH,Steven Fein, MD, MPH,Ashley Benson, MD Experts on iron deficiency anemia discuss practical tools they utilize for the clinical administration of intravenous iron.
How to Manage Infusion Reactions with Intravenous Iron
ByMichael Auerbach, MD,Layla Van Doren, MD,Jordan Axelrad, MD, MPH,Steven Fein, MD, MPH,Ashley Benson, MD Steven Fein, MD, MPH, shares insights on the management of infusion reactions seen in patients receiving intravenous iron.
Infusion Reactions to Intravenous Iron
ByMichael Auerbach, MD,Layla Van Doren, MD,Jordan Axelrad, MD, MPH,Steven Fein, MD, MPH,Ashley Benson, MD Layla Van Doren, MD, discusses the management of complement activation-related pseudo-allergy (CARPA) in patients receiving intravenous iron infusions.
Safety of Intravenous Iron
ByMichael Auerbach, MD,Layla Van Doren, MD,Jordan Axelrad, MD, MPH,Steven Fein, MD, MPH,Ashley Benson, MD A panel of experts on iron deficiency anemia discuss the safety of intravenous iron infusions, highlighting data from clinical studies.
Dose Timing with Intravenous Iron
ByMichael Auerbach, MD,Layla Van Doren, MD,Jordan Axelrad, MD, MPH,Steven Fein, MD, MPH,Ashley Benson, MD Experts on iron deficiency anemia share clinical practices for patients receiving intravenous iron.
Generic Formulations of Iron
ByMichael Auerbach, MD,Layla Van Doren, MD,Jordan Axelrad, MD, MPH,Steven Fein, MD, MPH,Ashley Benson, MD Michael Auerbach, MD, provides an overview of the utility of generic formulations of iron in addressing iron deficiency anemia.
Overview of Iron Formulations
ByMichael Auerbach, MD,Layla Van Doren, MD,Jordan Axelrad, MD, MPH,Steven Fein, MD, MPH,Ashley Benson, MD A panel of experts on iron deficiency anemia discusses formulations available for iron infusions, highlighting factors that inform selection.
Real-World Applications of Intravenous Iron
ByMichael Auerbach, MD,Layla Van Doren, MD,Jordan Axelrad, MD, MPH,Steven Fein, MD, MPH,Ashley Benson, MD Experts in hematology, gastroenterology, and obstetrics and gynecology detail their experiences with the real-world application of intravenous iron in their clinics.
Unmet Need for Addressing the Use of IV Iron
ByMichael Auerbach, MD,Layla Van Doren, MD,Jordan Axelrad, MD, MPH,Steven Fein, MD, MPH,Ashley Benson, MD An obstetrician-gynecologist addresses the unmet clinical needs in the treatment of patients with iron deficiency anemia, particularly for pregnant patients.
The Clinical Role of Intravenous Iron
ByMichael Auerbach, MD,Layla Van Doren, MD,Jordan Axelrad, MD, MPH,Steven Fein, MD, MPH,Ashley Benson, MD The expert panel discusses why intravenous iron replacement used to be associated with unacceptable toxicity and has become much more tolerable over time.
Confirming Iron Deficiency Diagnosis
ByMichael Auerbach, MD,Layla Van Doren, MD,Jordan Axelrad, MD, MPH,Steven Fein, MD, MPH,Ashley Benson, MD Ashley Benson, MD, discusses the most recent International Federation of Gynecology and Obstetrics (FIGO) statement on iron deficiency and anemia in women and girls.
Common Causes of Iron Deficiency
ByMichael Auerbach, MD,Layla Van Doren, MD,Jordan Axelrad, MD, MPH,Steven Fein, MD, MPH,Ashley Benson, MD Hematologists, a gastroenterologist, and an obstetrician-gynecologist discuss the common causes of iron deficiency seen in clinical practice.
Defining Iron Deficiency
ByMichael Auerbach, MD,Layla Van Doren, MD,Jordan Axelrad, MD, MPH,Steven Fein, MD, MPH,Ashley Benson, MD The panel provides a broad overview of the treatment of patients with iron deficiency, highlighting diagnostic practices.
Introduction and Overview of the Physiological Role of Iron Metabolism
ByMichael Auerbach, MD,Layla Van Doren, MD,Jordan Axelrad, MD, MPH,Steven Fein, MD, MPH,Ashley Benson, MD A panel of experts on iron deficiency anemia introduce themselves and provide an overview of the physiology of iron metabolism and iron deficiency.
Resources for Patients and Providers on Adalimumab Biosimilars
ByJamie T. Brogan, MSN, APRN, FNP-BC,Kostas N. Botsoglou, MD,Jordan Axelrad, MD, MPH,Sophia Humphreys, PharmD, MHA,Peter Lio, MD Expert providers in inflammatory diseases provide additional resources on biosimilars and adalimumab biosimilar for patients and providers.
The Role of Nurses and Support Personal in Educating Patient on Adalimumab Biosimilars
ByJamie T. Brogan, MSN, APRN, FNP-BC,Kostas N. Botsoglou, MD,Jordan Axelrad, MD, MPH,Sophia Humphreys, PharmD, MHA,Peter Lio, MD Providers in inflammatory diseases discuss the instrumental role nurses and support staff play in educating patients on adalimumab biosimilars.
Common Questions From Patients About Adalimumab Biosimilars
ByJamie T. Brogan, MSN, APRN, FNP-BC,Kostas N. Botsoglou, MD,Jordan Axelrad, MD, MPH,Sophia Humphreys, PharmD, MHA,Peter Lio, MD Drs Lio, Botsoglou, and Alexrad discuss the most asked questions and common concerns patients have on adalimumab biosimilars.
Copay Assistance Programs for Adalimumab Biosimilars
ByJamie T. Brogan, MSN, APRN, FNP-BC,Kostas N. Botsoglou, MD,Jordan Axelrad, MD, MPH,Sophia Humphreys, PharmD, MHA,Peter Lio, MD Clinicians and a pharmacist discuss how they are managing access and assistance with copay assistance program in their practices.
The Role of Health Care Providers on Encouraging Adalimumab Biosimilar Use
ByJamie T. Brogan, MSN, APRN, FNP-BC,Kostas N. Botsoglou, MD,Jordan Axelrad, MD, MPH,Sophia Humphreys, PharmD, MHA,Peter Lio, MD Healthcare providers in inflammatory diseases talk about the role they have on encouraging adalimumab biosimilar use in clinical practice.
Clinical Experience With Initiating Adalimumab Biosimilars
ByJamie T. Brogan, MSN, APRN, FNP-BC,Kostas N. Botsoglou, MD,Jordan Axelrad, MD, MPH,Sophia Humphreys, PharmD, MHA,Peter Lio, MD Specialists in rheumatology, dermatology and gastrointestinal disease share their clinical experience on initiating or switching their patients on adalimumab biosimilars.
Switching From Adalimumab to a Biosimilar
ByJamie T. Brogan, MSN, APRN, FNP-BC,Kostas N. Botsoglou, MD,Jordan Axelrad, MD, MPH,Sophia Humphreys, PharmD, MHA,Peter Lio, MD Specialists in rheumatology, dermatology and gastrointestinal disease discuss the evidence on efficacy and safety on switching patient to an adalimumab biosimilar.
Selecting Between Adalimumab Biosimilars for Your Patients
ByJamie T. Brogan, MSN, APRN, FNP-BC,Kostas N. Botsoglou, MD,Jordan Axelrad, MD, MPH,Sophia Humphreys, PharmD, MHA,Peter Lio, MD Providers in rheumatology, dermatology and gastrointestinal disease talk about how they are selecting between the various adalimumab biosimilars available for their patients.
Strategies to Increase Adalimumab Biosimilar Uptake in Clinical Practice
ByJamie T. Brogan, MSN, APRN, FNP-BC,Kostas N. Botsoglou, MD,Jordan Axelrad, MD, MPH,Sophia Humphreys, PharmD, MHA,Peter Lio, MD A clinical pharmacist and specialists in rheumatology, dermatology, and gastrointestinal disease share strategies in how to increase the uptake of adalimumab biosimilar among providers.
The Role of Pharmacy Benefit Managers and Payers in Accessing Adalimumab Biosimilars
ByJamie T. Brogan, MSN, APRN, FNP-BC,Kostas N. Botsoglou, MD,Jordan Axelrad, MD, MPH,Sophia Humphreys, PharmD, MHA,Peter Lio, MD A clinical pharmacist discusses the role of pharmacy benefit managers and payers in accessibility of adalimumab biosimilars.
Impact of the Launch of Adalimumab Biosimilars in Different Clinical and Pharmacy Settings
ByJamie T. Brogan, MSN, APRN, FNP-BC,Kostas N. Botsoglou, MD,Jordan Axelrad, MD, MPH,Sophia Humphreys, PharmD, MHA,Peter Lio, MD Experts talk about the impact of the launch of adalimumab biosimilar on their clinical practices and pharmacy.
The Safety and Efficacy of Adalimumab Biosimilars in Inflammatory Diseases
ByJamie T. Brogan, MSN, APRN, FNP-BC,Kostas N. Botsoglou, MD,Jordan Axelrad, MD, MPH,Sophia Humphreys, PharmD, MHA,Peter A. Lio, MD, Northwestern University Feinberg School of Medicine Specialists in rheumatology, dermatology and gastrointestinal disease discuss clinical trials that have shown safety and efficacy of adalimumab biosimilars in inflammatory diseases.
